FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula I
or its pharmaceutically acceptable salt. In formula I: each of A, D, E, G, J, L, M and Q is a carbon atom; each of R1 and R2 is independently selected from hydrogen and halogen; each of R3 and R5 is hydrogen; R4 is selected from hydrogen and (C1-C6)alkyl; R6 and R7 are linked to each other in form of pyrrolidinone ring, imidazolidinone ring, 7-member mono- or a bicyclic ring or 10-member mono- or bicyclic ring optionally substituted with one or more halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C10)cycloalkyl or (C6-C10) with aryl. Any of carbon atoms (C1-C6)alkyl, (C1-C6)alkoxy, (3–10) -found cycloalkyl, (C6-C10) aryl, pyrrolidinone ring, imidazolidinone ring, 7-member mono- or bicyclic ring or 10-member mono- or bicyclic ring is independently optionally substituted with 1–3 substituents R14, where each R14 is independently selected from halogen, (C1-C6) alkoxy, (C1-C6) alkyl, - (CR11R12)e(3–10) member cycloalkyl and - (CR11R12)e(C6-C10) aryl. Any of the nitrogen atoms of the pyrrolidone ring, imidazolidinone ring, 7-member mono- or bicyclic ring or 10-member mono- or bicyclic ring is independently optionally substituted with (C1-C6) alkyl, - (CR11R12)e(3-10) -scribed cycloalkyl and - (CR11R12)e(C6-C10) with aryl. R11 and R12 independently represent hydrogen or (C1-C6) alkyl, a and b independently represent 1, 2, 3 or 4 and e is 0, 1, 2, 3, 4 or 5. Also disclosed are versions of the compound of formula I, a pharmaceutical composition, methods of treating and methods of softening the mediated Cry disease or disorder.
EFFECT: disclosed compounds are capable of modulating cryptochomes (Cry) and can be used for treating Cry-related diseases or disorders.
46 cl, 22 dwg, 4 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CARBAZOLE-CONTAINING SULFONAMIDES AS MODULATORS OF CRYPTOCHROME | 2013 |
|
RU2654484C1 |
| NOVEL COMPOUNDS, ISOMERS THEREOF OR PHARMACUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUNDS | 2007 |
|
RU2448108C2 |
| PHENYLCARBAMATES AND USE THEREOF AS ENZYME INHIBITORS OF HYDROLASES OF FATTY ACID AMIDES (FAAH) AND DOPAMINE RECEPTOR D3 (D3DR) MODULATORS | 2014 |
|
RU2693457C2 |
| SUBSTITUTED CHROMANS | 2015 |
|
RU2718060C2 |
| 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND 6-AMINO-2-(4-SUBSTITUTED-PHENYL)-PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES | 2014 |
|
RU2771326C2 |
| 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND 6-AMINO-2-(4-SUBSTITUTED-PHENYL)-PYRIMIDINE-4-CARBOXYLATES AND THEIR APPLICATION AS HERBICIDES | 2014 |
|
RU2652132C2 |
| DIPICOLYLAMINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | 2015 |
|
RU2703454C2 |
| COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
| INDOLOPYRROLOCARBAZOLE DERIVATIVES OF SUGARS, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF AND METHOD OF INHIBITION OF TUMOR PROLIFERATION | 1997 |
|
RU2167880C2 |
| CYCLOALKANE DERIVATIVE | 2013 |
|
RU2635354C2 |
